What is the optimal strategy for managing primary care patients with an uncomplicated acute sore throat? Comparing the consequences of nine different strategies using a compilation of previous studies

Ronny Gunnarsson, Ulrich Orda, Bradley Elliott, Clare Heal, Chris Del Mar

ABSTRACT

Objective Identifying optimal strategies for managing patients of any age with varying risk of acute rheumatic fever (ARF) attending for an apparently uncomplicated acute sore throat, also clarifying the role of point-of-care testing (POCT) for presence of group A beta-haemolytic Streptococcus (GABHS) in these settings.

Design We compared outcomes of adhering to nine different strategies for managing these patients in primary healthcare.

Setting and participants The nine strategies, similar to guidelines from several countries, were tested against two validation data sets being constructs from seven prior studies.

Main outcome measures The proportion of patients requiring a POCT, prescribed antibiotics, prescribed antibiotics having GABHS and finally having GABHS not prescribed antibiotics, if different strategies had been adhered to.

Results In a scenario with high risk of ARF, adhering to existing guidelines would risk many patients ill from GABHS left without antibiotics. Hence, using a POCT on all of these patients minimised their risk. For low-risk patients, it is reasonable to only consider antibiotics if the patient has more than low pain levels despite adequate analgesia, 3–4 Centor scores (or 2–3 FeverPAIN scores or 3–4 McIsaac scores) and a POCT confirming the presence of GABHS. This would require testing only 10%–15% of patients and prescribing antibiotics to only 3.5%–6.6%.

Conclusions Patients with high or low risk for ARF needs to be managed very differently. POCT can play an important role in safely targeting the use of antibiotics for patients with an apparently uncomplicated acute sore throat.

Fear of acute rheumatic fever and other complications

A sore throat caused by GABHS can result in supplicative complications, such as peritonsillar abscess (quinsy), otitis media, sinusitis and skin infections, as well as non-suppurative ones, such as acute rheumatic fever (ARF) and poststreptococcal glomerulonephritis. Suppurative complications after a sore throat are unusual and rarely dangerous in high-income countries.

ARF, and the subsequent rheumatic heart disease (RHD), is the most serious and feared complication with a worldwide estimated 319,400 deaths in 2015. Hence, historically an emphasis was put on the risk and prevention of ARF. Most high-income countries has seen a step decline in the incidence of ARF. However, the risk for ARF in high-income countries may still have to be considered in a few high-risk individuals such as immigrants.
from low-income countries as well as some groups of first nation people. The estimated age-standardised prevalence of RHD per 100 000 population was for low-income countries 444 and for high-income countries 3.4, respectively.

Antibiotic treatment of patients with a sore throat reduces the incidence of ARF. Adherence to secondary prophylaxis after one episode of ARF is poor, emphasising the importance of preventing the first episode. Some recommendations before the era of point-of-care testing (POCT) were to swab for GABHS and treat accordingly, however, this caused delay and often an additional consultation. Subsequently, it became common practice in many high-income countries to prescribe penicillin routinely to patients attending with a sore throat despite a step decline in the incidence of ARF.

Other bacteria than GABHS
Streptococcus dysgalactiae subspecies Equisimilis (SDSE), Fusobacterium necrophorum (FN) and other bacteria are commonly found. FN may also cause the rare Lemierre’s disease. It has been suggested that prescribing antibiotics to patients with an uncomplicated acute sore throat harbouring FN may reduce the incidence of Lemierre’s syndrome, although there are to date no empirical studies supporting this. Case-control studies conclude SDSE and FN are not as important as GABHS in patients with an apparently uncomplicated acute sore throat. Furthermore, most empirical studies show antibiotics have no effect on symptom relief in the absence of GABHS, with a few exceptions showing a borderline effect in adult patients with SDSE. Despite this some practitioners perceive anything bacterial requires antibiotic treatment.

Clinical scoring algorithms
Various scoring algorithms were developed to identify patients with a lower probability of having GABHS, including the Centor criteria, the FeverPAIN scores and the McIsaac scores. However, these algorithms are poorly adopted in clinical practice which may contribute to inappropriate antibiotic prescribing.

Changes over time in high-income countries
A century ago, most countries had high incidences of ARF. However, this has declined dramatically over time in high-income countries. There are some exceptions, such as Australia and New Zealand, which still have high incidences of ARF in some risk groups.

In high-income countries, the main reason for antibiotic treatment is to reduce symptoms. Intervention studies show a minor reduction of symptoms in patients with a sore throat with a combination of presumed viral or bacterial origin. Antibiotics have a modest effect in reducing acute symptoms if GABHS is present in children, and in children and adults combined. Placebo controlled studies that performed a separate analysis for GABHS-positive and GABHS-negative patients found a statistically significant effect of antibiotics in GABHS-positive patients but not in those GABHS-negative. A subgroup analysis in a recent meta-analysis found a better effect of antibiotics if GABHS is present.

However, antibiotics have adverse effects such as increased antibiotic resistance, allergies, short-term gastrointestinal disturbances, candidiasis, potentially a reduction in development of long-term immunity against GABHS, increased risk for colorectal cancer, increased risk for rheumatic arthritis and possibly also increased risk for obesity. The modest reduction in acute symptoms has to be weighed against these potential negative effects.

Modern guidelines and their impact in high-income countries
There is now a plethora of different guidelines in high-income countries advising against routine use of antibiotics. Existing guidelines for management of patients with a sore throat focus on GABHS. However, they vary widely. While guidelines are important in theory and likely to have some impact, some practitioners seem to develop their own individual approach to manage patients presenting with a sore throat that differs significantly from any guideline. Some practitioners prescribe antibiotics to all, or nearly all, patients with a sore throat, perhaps in an attempt to reduce risks, to meet patient expectations or to reduce risks of litigation. However, the art of medicine is rarely about achieving zero risk but rather to weigh different risks and benefits.

The problem is twofold. First, that there are contradicting guidelines for managing patients with a sore throat and second, that many practitioners do not adhere to any of them and instead rely on their own approach and clinical judgement. General practitioner (GPs) are highly skilled in improvising when faced with complex problems such as frail patients with multimorbidity or patients having a mixture of biomedical and psychosocial problems. In these situations, the GP makes a very good compromise between different guidelines or develops a plan where no guideline exists. These situations cannot be resolved without a high degree of improvisation requiring a strong belief in one’s own clinical judgement. However, most patients attending for a sore throat are relatively young and do not have relevant comorbidities so typically this problem is straightforward. A very simple and specific guideline, such as those for the uncomplicated acute sore throat, leave no room for improvisation, but this may not be compatible with the nature of many, otherwise highly skilled, GPs.

Point-of-care testing
Throat swabs send for bacteriology are hampered by the delay in obtaining results. However, high-quality POCTs, delivering a result in minutes, are more useful. Some studies find little benefit of POCT in a low risk setting. Other studies, in a mixture of high-risk and low-risk patients, suggest they produce a modest reduction of antibiotic prescribing but importantly,
they make antibiotic prescribing better targeted. The adoption of POCT varies due to concerns with accuracy of the test, although this concern may be misplaced due to misconceptions:

1. The belief that a rapid POCT is not sensitive enough to reliably rule out the presence of GABHS. The POCT has, traditionally been compared with culture as reference standard, a technique introduced in 1903. Modern POCT has been perceived to have a sensitivity below 90% when compared with culture as reference standard. However, using more advanced reference standards has shown that, when there is diagnostic discrepancy between modern POCT and culture, POCT are more likely to be correct. Several modern POCT may have higher sensitivity than culture. There are also new small POCT molecular tests with a >95% sensitivity compared with in-house PCR. Hence, modern high-quality POCT does not have a sensitivity inferior to culture, though this remains an educational challenge.

2. There is a belief that the POCT cannot distinguish between carriers and patients ill from GABHS, thus rendering the POCT useless. However, this is a misunderstanding of the problem. A high-quality POCT, used correctly, showing no presence of GABHS has a negative predictive value near 99% irrespective of the proportion of carriers of GABHS. Carriers will only influence the clinical value of a POCT positive for GABHS (the positive predictive value) but, in most patients the test will be negative and hence very reliable and clinically useful. Hence, a modern POCT will always work well as a stopping rule to stop incorrect antibiotic prescribing.

3. An assumption that patients ill from a non-GABHS bacterium should be treated with antibiotics, making the POCT useless since these bacteria are not detectable by the type of POCT mostly used in today’s PHC. This is linked to the misconception that anything that is bacterial requires antibiotics. To rely on clinical symptoms and signs alone, ignoring the additional information from a modern high-quality POCT, increases antibiotic prescribing and leaves a significant proportion of patients ill from GABHS without antibiotics, which may not be acceptable in a situation with an elevated risk for ARF.

The remaining dilemma

In many high-income countries, 40%–80% of patients attending PHC for an apparently uncomplicated acute sore throat are prescribed antibiotics. Furthermore, many patients in a high-risk setting attending for a sore throat, and with proven presence of GABHS, are not prescribed antibiotics. This makes it worth to investigate the consequences of using different strategies in a constructed data validation set with known prevalence of GABHS. Our goal was to identify optimal strategies for scenarios with low as well as high risk of ARF.

METHODS

Selection of strategies to be evaluated

Most guidelines in high-income countries advise against the routine use of antibiotics in patients with minor discomfort. Hence, strategies using a cut-off of ≥2 or ≥3 Centor criteria to guide the use of POCT and antibiotic prescribing were evaluated and the consequences were estimated. These strategies does not include the scenario where you want to identify all patients with a GABHS infection irrespective of the magnitude of symptoms, as in patients at high risk of ARF. Furthermore, the strategies mentioned above do not cover the situation where avoidance of antibiotic use is the main focus. Hence, the strategies of prescribing antibiotics to all patients, using a POCT on all patients, never considering antibiotic use and including analgesics in a decision tree were also evaluated. Some of these strategies correspond to existing guidelines (table 1—with no ambition to identify all guidelines aligning with the strategies to be evaluated).

Data set for validation of strategies

We identified seven publications stating the proportion of patients harbouring GABHS split into Centor scores 0–4 and providing actual numbers or detailed proportions. Two publications, Wighton et al and Fine et al were retrospective chart reviews where only patients who had their throat swabbed were included. Two studies by Pallon et al included patients first triaged by a nurse to sort out those with less probability for harbouring GABHS. Previous studies prospectively including unselected patients had a higher prevalence of patients with 0 Centor criteria compared with the publications including selected patients. Consequently, we decided to create two separate validation data sets, each being the weighted average of included studies (table 2).

Monitoring of adverse events and safety procedures

Due to the nature of this study, no adverse events were expected nor observed.

Outcome measures and statistical analysis

The outcome measures were the proportion of patients requiring a POCT, prescribed antibiotics, prescribed antibiotics and having GABHS and finally having GABHS not prescribed antibiotics. This was calculated for the following strategies: (A) prescribe antibiotics to all patients, (B) test all patients and prescribe antibiotics if positive, (C) prescribe antibiotics if Centor criteria is 3–4 (as in Australia), (D) prescribe antibiotics if Centor criteria is 3–4 (as in Australia), (E) if Centor criteria is 2–4 test patient and prescribe antibiotics if positive, (F) if Centor criteria is 3–4 test patient and prescribe antibiotics if positive, (G) if Centor criteria is 2–4 and pain is more than mild after analgesics test patient and prescribe antibiotics if positive, (H) if Centor criteria is 3–4 and pain is more than mild after analgesics test.
patient and prescribe antibiotics if positive, (I) never test nor prescribe antibiotics (as in the Netherlands).91

**Patient and public involvement**

Patients were not involved in the development of plans for design, outcome measures or implementation of the study conduct. No patients were asked to advise on the interpretation or writing of results.

**RESULTS**

The strategies to prescribe antibiotics to all patients (row A in table 3) or to test all patients and prescribe antibiotics to all with a positive test (row B in table 3) would have ensured all of those having GABHS were given antibiotics (the rightmost column in row A and B in table 3). The lowest rate of antibiotic prescribing is achieved using the strategy of no antibiotic use (row I in table 3). If any use of antibiotics is allowed, the lowest prescribing rate, 3.5%–6.6%, would have been achieved by the strategy to only test if Centor criteria is 3–4, the pain is more than mild after adequate dose of analgesics and then only prescribe antibiotics if the test is positive (row H in table 3).

**DISCUSSION**

Consequences of adhering to different strategies vary dramatically and the choice of optimal strategy should be guided by the local prevalence of RHD as a marker of risk in the local setting. However, local healthcare providers may have different opinions as to which prevalence of RHD constitutes high, moderate or low risk. Hence, we suggest management in these different settings without defining a specific cut of in the prevalence of RHD to constitute a high-risk, moderate-risk or low-risk setting.

**Strength and limitations of the data set for validation**

The data sets for validation of strategies constitute a mix of studies including children and/or adults from various countries and continents. However, reasonable variations in the validation data sets would not alter the conclusions in this study.

**Suggested management if the risk for ARF is high**

Primary prevention of ARF is the main goal in this scenario. Hence, none of patients at high risk of ARF and harbouring GABHS, irrespective of Centor scores, should miss out on antibiotics (the rightmost column in table 3). We have seen that not testing patients in a high risk setting leaves a significant proportion of patients at high risk of ARF truly ill from GABHS without antibiotics.33 The strategy best achieving adequate antibiotic cover is to test all patients if POCTs are available (row B in table 3). Prescribing antibiotics to all patients attending for a sore throat (row A in table 3) would be the second best strategy if POCTs are unavailable. However, the latter strategy will lead to many unnecessary antibiotic prescriptions to patients not harbouring GABHS.

**Suggested management if the risk for ARF is moderate**

In this setting, it might be acceptable that patients with mild symptoms are left untreated despite some of them harbouring GABHS. The best strategy is to test all patients (row B in table 3) if POCTs are easily available. The

### Table 1 Some existing guidelines for managing patients with an uncomplicated acute sore throat and low risk for acute rheumatic fever

| Guideline | Short summary of the threshold to prescribe antibiotics | Statement about throat swabbing | Statement about analgesics* |
|-----------|------------------------------------------------------|-------------------------------|---------------------------|
| **Therapeutic guidelines Australia** | It is reasonable to prescribe antibiotics if symptoms are severe (Centor scores are not mentioned but the described symptoms correspond well with 3–4 Centor criteria) | Throat swabs are not mentioned at all | Paracetamol or Non-steroidal anti-inflammatory drugs (NSAIDs) can be used |
| **European Society of Clinical Microbiology and Infectious Diseases (ESCMID)** | Consider antibiotics if 3–4 Centor criteria | Throat swabs are not necessary but may be used in patients with 3–4 Centor criteria. | All patients may try systemic paracetamol or ibuprofen. |
| **Netherlands** | Only to patients with peritonsillar infiltrate/abscess. | Throat swabs should be avoided | Paracetamol in adequate dose |
| **The Scottish Intercollegiate Guidelines Network (SIGN)** | The Centor clinical prediction score should be used to assist the decision on whether to prescribe an antibiotic (no cut-off is provided but seems like Centor 2–4) | Throat swabs should be avoided | Ibuprofen (paracetamol if intolerant to ibuprofen) |
| **Sweden** | Only consider antibiotics if 3–4 Centor criteria and if a point of care test for GABHS is positive | Only if 3–4 Centor criteria and if antibiotics is considered. | All patients may try analgesics. |
| **UK** | Consider antibiotics if 3–4 Centor criteria or 4–5 FeverPAIN scores. | Throat swabs have no clear advantage. | All patients may try systemic paracetamol or ibuprofen. |
| **USA** | Prescribe antibiotics if 3–4 Centor criteria and if a point of care test for GABHS is positive | Only if 3–4 Centor criteria. | Adults should be offered analgesics |

*Analgesics are mentioned in all guidelines as a parallel information but it is not being a direct part of a decision tree like ‘don’t consider antibiotics if analgesics reduce pain significantly so no pain or only mild pain remains’. GABHS, group A beta-haemolytic Streptococcus.
### Table 2  Previous data sets with detailed information on prevalence of GABHS related to the number of Centor criteria

| Year | n   | Study            | Age year | 0 centor criteria | 1 centor criteria | 2 centor criteria | 3 centor criteria | 4 centor criteria |
|------|-----|------------------|----------|-------------------|-------------------|-------------------|-------------------|-------------------|
|      |     |                  | Prevalence* | GABHS pos† | Prevalence* | GABHS pos† | Prevalence* | GABHS pos† | Prevalence* | GABHS pos† |
|      |     |                  | % (n)     | % (n)     | % (n)     | % (n)     | % (n)     | % (n)     | % (n)     | % (n)     |
| 2015 | 312 | Centor          | 15–30     | 13 (39)   | 5.1 (2)   | 33 (104)  | 4.8 (5)   | 34 (106)  | 5.7 (6)   | 14 (44)   | 6.1 (19)  | 11 (2)     |
| 2016 | 101 | Orda            | 3–15      | 34 (34)   | 12 (4)    | 39 (39)   | 21.8      | 15 (15)   | 53.8      | 8.9 (9)   | 56 (9)    | 4.0 (4)    | 25 (1)     |
| 2021 | 281 | Gunnarsson      | 0–96      | 23 (65)   | 28 (18)   | 34 (96)   | 15 (14)   | 27 (76)   | 36 (27)   | 12 (35)   | 57 (20)   | 3.2 (9)    | 78 (7)     |
|      | 694 | Validation set A| 20 (138)  | 17 (24)   | 34 (239)  | 11 (27)   | 28 (197)  | 21 (41)   | 13 (88)   | 35 (31)   | 4.6 (32)  | 31 (10)    |
| 1986 | 405 | Wigton          | >12       | 7.6 (39)  | 2.6 (1)   | 27 (137)  | 14 (19)   | 31 (163)  | 23 (37)   | 2.3 (12)  | 45 (9)    | 11 (57)    | 54 (31)    |
| 2012 | 142 | Fine            | >3        | 9.6 (13 603) | 7 (952)   | 32 (45 080) | 12 (5410) | 33 (47 167) | 21 (9905) | 19 (26 769) | 38 (10 172) | 6.7 (9462) | 57 (5390)  |
| 2021 | 77  | Pallon          | 0–14      | 7.8 (6)   | 33 (2)    | 25 (19)   | 32 (6)    | 29 (22)   | 59 (13)   | 39 (30)   | 57 (17)   | 0 (0)      | -          |
| 2021 | 220 | Pallon          | 15–44     | 7.3 (16)  | 13 (2)    | 23 (50)   | 12 (6)    | 31 (69)   | 23 (16)   | 25 (54)   | 44 (24)   | 14 (31)    | 58 (18)    |
|      | 142 | Validation set B| 9.6 (13 664) | 7.0 (957) | 32 (45 286) | 12 (5441) | 33 (47 418) | 21 (9971) | 19 (26 865) | 38 (10 218) | 6.7 (9550) | 57 (5442)  |

*Proportion of patients having this number of Centor criteria fulfilled.
†Proportion of patients with this number of Centor criteria harbouring GABHS.
‡Additional information was obtained after contact with the authors to clarify the proportion of patients harbouring GABHS split into Centor categories.
§Exact numbers of individuals are calculated from stated percentages. In this process, we calculate to the nearest whole integer. We then calculate new percentages from these exact numbers. Our percentages differ slightly from Wigton and Fine’s papers. Wigton and Fine provide percentages with low precision presumably resulting in an insignificant rounding error. This explains the small insignificant difference in percentages.

GABHS, group A beta-haemolytic Streptococcus.
second best strategy, if POCTs are available but of limited supply, is to adhere to the strategy described in row E, test if the patient has 2–4 Centor scores and prescribe antibiotics to all patients with a positive test. The consequences would be that a similar proportion of patients are prescribed antibiotics as if everyone was tested but only roughly half of the patients require testing. The downside is that 20%–38% of patients with a sore throat harbouring GABHS miss out on antibiotics. The third best option, if POCTs are completely unavailable, would be to prescribe antibiotics to all patients attending for a sore throat. Again, the downside is the overtreatment as described above.

**Suggested management if the risk for ARF is negligible**

Here the use of antibiotics for preventing ARF is unnecessary, and is of small benefit for reducing symptoms.37 Hence, the primary goal is to safely reduce antibiotic usage as much as possible. The optimal management in this situation is patient-centred care where the clinician presents available evidence of the benefits and harms of antibiotics. This is followed by a joint discussion whether antibiotics are worthwhile here, in other words, shared decision making.92

The Netherlands have the most restrictive guideline prohibiting any antibiotic prescribing to otherwise healthy patients attending for an uncomplicated acute sore throat.91 Despite this GPs in the Netherlands prescribe antibiotics to approximately 50% of patients attending with a sore throat35,37 suggesting that this overly restrictive guideline has limited influence. It will be difficult to deny antibiotic treatment for those having intense symptoms despite adequate analgesics, presence of GABHS and requesting antibiotics. Hence, stating that otherwise healthy patients with uncomplicated acute sore throat should never be prescribed antibiotics at their first visit is unlikely to work in reality and potentially unethical. A sensible compromise that can work in real life should be made.

The main reason for considering antibiotics is to reduce pain and fatigue, and there is no need for antibiotics if analgesics work well in low-risk patients. Many current guidelines recommend the use of analgesics for symptomatic treatment (table 1) but none of the guidelines presented

### Table 3 Different strategies for managing patients with a sore throat and their consequences

| Different strategies for testing presence of GABHS and prescribing antibiotics (AB) | Resembling guidelines in | Validation data set | Requiring testing for GABHS* | Requiring antibiotic prescribing† | Proportion of those prescribed antibiotics harbouring GABHS‡ | Proportion of those not harbouring GABHS§ |
|---|---|---|---|---|---|---|
| A. Prescribe AB to all patients | (None) | A | 0.0% | 100% | 19% | 0.0% |
| B. Test all patients—AB only if test is positive | (None) | A | 100% | 19% | 100% | 0.0% |
| C. No testing. Prescribe AB if Centor is 2–4 | Scotland | A | 0.0% | 46% | 26% | 38% |
| D. No testing. Prescribe AB if Centor is 3–4 | Australia, European Society of Clinical Microbiology and Infectious Diseases (ESCMID), UK | A | 0.0% | 17% | 34% | 69% |
| E. Test if Centor is 2–4—AB only if test is positive | (None) | A | 46% | 12% | 100% | 38% |
| F. Test if Centor is 3–4—AB only if test is positive | Sweden | A | 17% | 5.9% | 100% | 69% |
| G. Test if Centor is 2–4 and pain is more than mild after analgesics—AB only if test is positive¶ | USA | A | 27% | 7.1% | 100% | 63% |
| H. Test if Centor is 3–4 and pain is more than mild after analgesics—AB only if test is positive¶ | (None) | A | 10% | 3.5% | 100% | 82% |
| I. Never test nor prescribe AB. Only advice on analgesics. | Netherlands | A | 0.0% | 0.0% | – | 100% |

*Proportion of patients tested when following the strategy for testing and prescribing antibiotics.
†Should be as low as possible in patients with no elevated risk for ARF or any other risk factors such as known immunodeficiency.
‡Should be as high as possible as we mainly have solid evidence for the effectiveness of antibiotics in the presence of GABHS.
§Should be as low as possible in patients at elevated risk for ARF.
¶Some patients have mild pain before analgesics and analgesics is assumed to further reduce the need for antibiotics.

**Open access**

Gunnarsson R, et al. BMJ Open 2022;12:e059069. doi:10.1136/bmjopen-2021-059069

---

**Table 3 Different strategies for managing patients with a sore throat and their consequences**

- **Resembling guidelines in**: Various countries and regions are listed, indicating different approaches to antibiotic prescribing and testing strategies.
- **Validation data set**: The table references data sets from different locations, such as Scotland and Australia, to validate the effectiveness of the strategies.
- **Requiring testing for GABHS**: This column indicates the percentage of patients requiring testing for GABHS, ranging from 0.0% to 100%.
- **Requiring antibiotic prescribing**: This column shows the percentage of patients who require antibiotic prescribing, with values ranging from 0.0% to 100%.
- **Proportion of those prescribed antibiotics harbouring GABHS**: This column presents the proportion of patients who were prescribed antibiotics and were found to have GABHS, with values ranging from 0.0% to 100%.
- **Proportion of those not harbouring GABHS**: This column indicates the proportion of patients who were not prescribed antibiotics and did not have GABHS, with values ranging from 0.0% to 100%.

### Notes

- **Table 3** provides a comprehensive overview of different strategies for managing patients with a sore throat, along with the consequences of each strategy.
- The table highlights the importance of balancing the need for antibiotics with potential harms, considering the risk of ARF and the effectiveness of antibiotics in various scenarios.
- The strategies vary from testing all patients to never testing or prescribing antibiotics, with implications for patient outcomes and healthcare costs.
- The table is structured to facilitate comparisons between different regions and their approaches to managing sore throats, emphasizing the importance of evidence-based practices.

---

**References**

- Gunnarsson R, et al. BMJ Open 2022;12:e059069. doi:10.1136/bmjopen-2021-059069
- Clinical guidelines may be available at the BMJ Open website or through relevant healthcare authorities.
in table 1 include analgesics in a decision tree for antibiotic prescribing. Analgesics should be part of a decision tree for low risk patients where antibiotics should only be considered if the patient has more than low pain after adequate analgesics, 3–4 Centor criteria26 27 (or 2–3 FeverPAIN scores28 29 or 3–4 McIsaac scores26 30 31) and a positive test confirming the presence of GABHS. Adhering to this recommendation results in the lowest rate of antibiotic prescribing if antibiotics are going to be used at all (row H in table 3). This strategy only requires a small proportion of patients being tested (10%–15%) and an even smaller proportion prescribed antibiotics (3.5%–6.6%).

Children versus adults
Asymptomatic carriers of GABHS are more common in children than in adults in most settings. However, the proportion of carriers in children can in some settings be very low and similar to the carrier rates seen in adults.34 Carriers will only influence the clinical value of a POCT positive for GABHS (the positive predictive value) but, in most patients the test will be negative and hence very reliable and clinically useful.65 The conclusion is that a modern POCT will always work well, in children and adults, as a stopping rule to stop incorrect antibiotic prescribing.66 ARF and RHD are more common in children but may occur also in adults. The main goal is to keep antibiotic prescribing at a minimum in a low risk setting while ensuring no patients attending for a sore throat and harbouring GABHS is left without antibiotics in a high risk setting. These goals are exactly the same for children as well as adults. Although adhering to our recommendations may result in a few unnecessary antibiotic prescriptions to children the same strategies were identified as optimal for children and adults.

Suggestions for future research
Highly skilled GPs successfully managing complex problems in patients with multimorbidity do not seem to comply well with existing simple guidelines for managing patients attending for an apparently uncomplicated acute sore throat. The drivers for GPs to make decisions are complex, and the relevance of the patient’s expectations should not be underestimated. A possible alternative might be to allow healthcare providers other than medical practitioners manage otherwise healthy patients at their first visit for an apparently uncomplicated acute sore throat. The drivers for GPs to make decisions are complex, and the relevance of the patient’s expectations should not be underestimated. A possible alternative might be to allow healthcare providers other than medical practitioners manage otherwise healthy patients at their first visit for an apparently uncomplicated acute sore throat. The drivers for GPs to make decisions are complex, and the relevance of the patient’s expectations should not be underestimated.

CONCLUSIONS
For patients at high risk of ARF, we suggest that the safe strategy is to test all patients with an apparently uncomplicated acute sore throat for presence of GABHS. Prescribing antibiotics to all patients at high risk would be the second best option if POCTs are unavailable, although this results in significant overprescribing of antibiotics.

In patients at low risk of ARF at their first visit we suggest adopting shared decision making and inform the patient that the most effective use of antibiotics is achieved by using the following strategy: primarily utilising analgesics as part of a decision tree where antibiotics should only be considered if the patient has more than low pain after adequate analgesics, 3–4 Centor criteria (or 2–3 Fever-PAIN scores or 3–4 McIsaac scores) and a positive POCT confirming the presence of GABHS.

It should be emphasised that these strategies may not be optimal in patients with signs of complications, in patients returning after a previous visit now being unwell, in patients with significant comorbidities and in hospitalised patients.
REFERENCES

1. André M, Vernby A, Odenholt I, et al. Diagnosis-prescribing surveys in 2000, 2002 and 2005 in Swedish general practice: consultations, diagnosis, treatments and diagnostic tests. *Scand J Infect Dis* 2008;40:648–54.

2. Tyström M, Beckman A, Målsjö M, et al. Reduction in antibiotic prescribing for respiratory tract infections in Swedish primary care - a retrospective study of electronic patient records. *BMJ Infect Dis* 2016;16:709.

3. Armstrong GL, Pinner RW. Outpatient visits for infectious diseases in the United States, 1980 through 1996. *Arch Intern Med* 1999;159:2531–6.

4. Little P, Stuart B, Hobbs FDR, et al. Predictors of supportive complications for acute sore throat in primary care: prospective clinical cohort study. *BMJ* 2013;347:f6867.

5. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. *N Engl J Med* 2017;377:713–22.

6. Catanzaro FJ, Stetson CA, Morris AJ, et al. The role of the streptococcus in the pathogenesis of rheumatic fever. *Am J Med* 1984;77:749–56.

7. Lennon D, Anderson P, Kerdernillid M, et al. First presentation acute rheumatic fever is preventable in a community setting: a school-based intervention. *Pediatr Infect Dis J* 2017;36:1113–8.

8. Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. *BMC Cardiovasc Disord* 2005;5:11.

9. Kevat PM, Reeves BM, Ruben AR, et al. Adherence to secondary prophylaxis for acute rheumatic fever and rheumatic heart disease: a systematic review. *Curr Cardioi Rev* 2017;13:155–66.

10. Lindbaek M, Halvorsen AE, Lerkær G, et al. Clinical symptoms and signs in sore throat patients with large colony variant beta-haemolytic streptococci groups C or G versus group A. *Br J Gen Pract* 2005;55:615–9.

11. Tiemstra J, M Postma JLF. Role of non-group a streptococci in acute pharyngitis. *J Am Board Fam Med* 2009;22:663–9.

12. Little P, Moore M, Hobbs FDR, et al. Primary care streptococcal management (PrISM) study: identifying clinical variables associated with Lancefield group A beta-haemolytic streptococci and Lancefield non-group a streptococcal throat infections from two cohorts of patients presenting with an acute sore throat. *BMJ Open* 2013;3:e003943.

13. Centor RM, Atkinson TP, Ratliiff AE, et al. The clinical presentation of Fusobacterium-potent and streptococcal-potent pharyngitis in a university health clinic: a cross-sectional study. *Ann Intern Med* 2015;162:241–7.

14. Hedin K, Bilder B, Lind M, et al. The aetiology of pharyngitis involving in adolescents and adults - Fusobacterium necrophorum is commonly found. *Clin Microbiol Infect* 2015;21:1263 e1–7.

15. Lemiére A, On carriage of septicaemia due to aerobic organisms. *The Lancet* 1936;227:701–3.

16. Osowicki J, Kapur S, Phuong LK, et al. The long shadow of Lemiére’s syndrome. *J Infect* 2017;74:S47–53.

17. Bank S, Christiansen K, Kristensen LH, et al. A cost-effectiveness analysis of identifying Fusobacterium necrophorum in throat swabs followed by antibiotic treatment to reduce the incidence of Lemiére’s syndrome and peritonsillar abscesses. *Eur J Clin Microbiol Infect Dis* 2013;32:71–8.

18. Gunnarsson RK, Manchal N. Grönholdt H, et al. Management of patients with sore throats in relation to guidelines: an interview study in Sweden. *Scand J Prim Health Care* 2014;32:193–9.

19. Fine AM, Nizet V, Mandl KD. Large-scale validation of the centroid and McIsaac scores to predict group A streptococcal pharyngitis. *Arch Intern Med* 2012;172:847–52.

20. Centor RM, Witherspoon JM, Dalton HP, et al. The diagnosis of strep throat in adults in the emergency room. *Med Decis Making* 1981;1:239–46.

21. Little P, Moore M, Hobbs FDR, et al. Primary care streptococcal management (PrISM) study: identifying clinical variables associated with Lancefield group A beta-haemolytic streptococci and Lancefield non-group a streptococcal throat infections from two cohorts of patients presenting with an acute sore throat. *BMJ Open* 2013;3:e003943.

22. Little P, Hobbs FDR, Moore M, et al. Clinical score and rapid antigen detection test to guide antibiotic use for sore throats: randomised controlled trial of PRISM (primary care streptococcal management). *BMJ* 2013;347:f5806.

23. McIsaac WJ, White D, Tannenbaum D, et al. A clinical score to reduce unnecessary antibiotic use in patients with sore throat. *CMAJ* 1998;158:75–83.

24. McIsaac WJ, Goel V, To T, et al. The validity of a sore throat score in family practice. *CMAJ* 2000;163:811–5.

25. Linder JA, Chan JC, Bates DW. Evaluation and treatment of pharyngitis in primary care practice: the difference between guidelines is largely academic. *Arch Intern Med* 2006;166:1374–9.

26. Guilford MC, Dregan A, Moore MV, et al. Continued high rates of antibiotic prescribing to adults with respiratory tract infection: survey of 568 UK general practices. *BMJ* 2014;4:e006245.

27. Orda U, Mifta B, Orda S, et al. Point of care testing for group A streptococci in patients presenting with pharyngitis will improve appropriate antibiotic prescription. *Emerg Med Australas* 2016;28:199–204.

28. Howie JG, Foggo BA. Antibiotics, sore throats and rheumatic fever. *J R Coll Gen Pract* 1985;35:223–4.

29. Australian Institute of Health and Welfare. Rheumatic heart disease and acute rheumatic fever in Australia: 1996-2012. Cardiovascular diseases series. Canberra 2013.

30. Spinks A, Gliaziou P, Del Mar CB. Antibiotics for treatment of sore throat in children and adults. *Cochrane Database Syst Rev* 2021;12:CD000023.

31. Nelson JD. The effect of penicillin therapy on the symptoms and signs of streptococcal pharyngitis. *Pediatr Infect Dis J* 1984;3:10–13.

32. Mielkeston DB, D’Amico F, Merson ME, et al. Standardized symptomatic treatment versus penicillin as initial therapy for streptococcal pharyngitis. *J Pediatr* 1988;113:1089–94.

33. Dagnelie CF, van der Graaf Y, De Melker RA. Does patients with sore throat benefit from penicillin? A randomized double-blind placebo-controlled clinical trial with penicillin V in general practice. *Br J Gen Pract* 1996;46:589–93.

34. Gillies M, Ranakusuma A, Hoffmann T, et al. Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. *CMAJ* 2015;192:E21–31.

35. Pichichero ME. The development of immunity sequelae or the carrier state following streptococcal pharyngitis. *Pediatr Ann* 1992;21:829–34.

36. Armstrong D, Dregan A, Ashworth M, et al. The association between colorectal cancer and prior antibiotic prescriptions: case control study. *Br J Cancer* 2020;122:912–7.

37. Van Q-Y, Zhao R, Wang Y, et al. Antibiotic use and risk of colorectal cancer: a meta-analysis of 412 450 participants. *Gut* 2020;69:2059–60.

38. Armstrong D, Dregan A, Ashworth M, et al. Influence of prior antibiotic use on risk of rheumatoid arthritis: case control study in general practice. *Rheumatology* 2020;59:1281–7.

39. Miller SA, Wu RKS, Oremus M. The association between antibiotic use in infancy and childhood overweight or obesity: a systematic review and meta-analysis. *Obes Rev* 2018;19:1463–75.

40. Rasmussen SH, Shrestha S, Bjergaard LG, et al. Antibiotic exposure in early life and childhood overweight and obesity: a systematic review and meta-analysis. *Diabetes Obes Metab* 2018;20:1508–14.

41. Leong KSW, Derrak JGB, Hofman RL, et al. Antibiotics, gut microbiome and obesity. *Clin Endocrinol* 2018;88:185–200.

42. National Institute for Health and Care Excellence (NICE). NICE Guideline [NG84] - Sore throat (acute): antimicrobial prescribing. London 2018.

43. Scottish Intercollegiate Guidelines Network (SIGN), SIGN Guideline [117] - Management of sore throat and indications for tonsillectomy. A national clinical guideline 2010.
73 Cohen JF, Cohen R, Bidet P, et al. Rapid-antigen detection tests for group A streptococcal pharyngitis: revisiting false-positive results using polymerase chain reaction testing. J Pediatr 2013;162:824–4.
74 Cohen DM, Russo ME, Jaggip P, et al. Multicenter clinical evaluation of the novel Alere i Cassa isothermal nucleic acid amplification test. J Clin Microbiol 2015;53:2256–61.
75 Gunnarsson RK, Lanke J. The predictive value of microbiologic diagnostic tests if asymptomatic carriers are present. Stat Med 2002;21:1773–85.
76 Gunnarsson RK. Dissertation: microbiologic diagnostic tests when asymptomatic carriers are present. aspects of the use of conventional throat and nasopharyngeal cultures as examples. Sweden: University of Gothenburg, 2001.
77 Orda U, Gunnarsson RK, Orda S. Etiologic predictive value of a rapid immunoassay for detection of group A streptococcal antigen from throat swabs in patients presenting with a sore throat. North American Primary Care Research Group (NAPCRG) Annual Meeting, Colorado Springs, US, 2016. Available: https://www.youtube.com/watch?v=tyhMetlK0yY;
78 Luo R, Sicker J, Vahdina F, et al. Diagnosis and management of group A streptococcal pharyngitis in the United States, 2011–2015. BMC Infect Dis 2019;19:139.
79 Tran J, Danchin M, C Steer A, et al. Management of sore throat in primary care. Aust J Gen Pract 2018;47:485–9.
80 Patel C, Green BD, Batt JM, et al. Antibiotic prescribing for tonsillopharyngitis in a general practice setting: can the use of modified Centor criteria reduce antibiotic prescribing? Aust J Gen Pract 2019;48:395–401.
81 Dallas A, van Driel M, Morgan S, et al. Antibiotic prescribing for sore throat: a cross-sectional analysis of the ReCeNT study exploring the habits of early-career doctors in family practice. Fam Pract 2016;33:302–8.
82 Damoiseaux RAMJ, Venekamp RP. [Prescribing antibiotics for sore throat: a persistent habit]. Ned Tijdsh Geneeskd 2015;159:A9419.
83 Tyrstrup M, van der Velden A, Engstrom S, et al. Antibiotic prescribing in relation to diagnoses and consultation rates in Belgium, the Netherlands and Sweden: use of European quality indicators. Scand J Prim Health Care 2017;35:10–18.
84 Wighton RS, Connolly P, Centor RM. Transportability of a decision rule for the diagnosis of streptococcal pharyngitis. Arch Intern Med 1986;146:81–3.
85 Pallon J, Röstö M, Sundqvist M, et al. The aetiology of pharyngotonsillitis in primary health care: a prospective observational study. BMC Infect Dis 2021;21:971.
86 Pallon J, Sundqvist M, Röstö M, et al. Presence of microorganisms in children with pharyngotonsillitis and healthy controls: a prospective study in primary healthcare. Infection 2021;49:715–24.
87 Antibiotic. Egt. Acute pharyngitis and/or tonsillitis. therapeutic guidelines (eTG Complete). Melbourne: Therapeutic Guidelines Limited, 2014.
88 Handläggning AV faryngotonsillit i öppenvård – NY rekommendation. Information från Läkarlakemedelsverket 2012:6:18–25.
89 Harris AM, Hicks LA, Qaseem A, et al. Antibiotic resistance in primary care: early, and are difficult to change. Antimicrobial resistance. Agency for Healthcare Research and Quality, 2015.
90 de Jonge H, Opstelten W, Werkgroep NHG-Standaard Acute keelpijn. [Revision of the Dutch College of General Practitioners practice guideline ‘acute sore throat’]. Ned Tijdschr Geneeskd 2015;159:A9456.
91 Coxeter P, Del Mar CB, McGregor L, et al. Interventions to facilitate shared decision making to address antibiotic use for acute respiratory infections in primary care. Cochrane Database Syst Rev 2015;11:CD010907.
92 de Jongh E, Opstelten W, Werkgroep NHG-Standaard Acute keelpijn. [Revision of the Dutch College of General Practitioners practice guideline ‘acute sore throat’]. Ned Tijdschr Geneeskd 2015;159:A9456.
93 Cox C, Jones M. An evaluation of the management of patients with sore throats by practice nurses and GPs. Br J Gen Pract 2000;50:872–6.
94 Fabrellas N, Sánchez C, Juvé E, et al. A program of nurse algorithm-guided care for adult patients with acute minor illnesses in primary care. BMC Fam Pract 2013;14:61.
95 Stuhr JK, Lykkegaard J, Kristensen JK. Danish GPs’ and practice nurses’ management of acute sore throat and adherence to guidelines. Fam Pract 2018.
96 Thornley T, Marshall G, Howard P, et al. A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies. J Antimicrob Chemother 2016;71:329–34.
97 Keesaly T. Sore throat. BMJ Clin Evid 2007:2007.